共查询到20条相似文献,搜索用时 468 毫秒
1.
2.
大蒜制剂、大蒜提取物和大蒜提取成分的抗肿瘤作用已有广泛的研究[1 ] 。蒜氨酸 (Alliin ,2 烯丙基半胱氨酸亚砜 )为大蒜活性成分的主要前体物质 ,蒜氨酸在蒜氨酸酶 (Alli inase ,EC 4 .4.1 .4)的催化作用下产生大蒜辣素 (Allicin ,二烯丙基硫代亚磺酸酯 )。本课题组发现蒜氨酸 +蒜氨酸酶生成的大蒜辣素 1 3h内基本稳定。据此 ,本文采用MGC 80 3和HeLa肿瘤细胞株 ,利用蒜氨酸 +蒜氨酸酶生成的大蒜辣素研究其体外的抗肿瘤作用及其作用机制。1 材料和方法1 .1 细胞培养及药物 细胞培养的传代接种见文献[2 ] 。蒜氨酸及蒜氨酸酶由新疆… 相似文献
3.
4.
5.
蒜辣素(allicin)及其前体蒜氨酸(alliin)已被认为是大蒜及其制品评价的标志成分。我们根据文献(1)和(3)改进了蒜辣素的合成和纯化方法,并用反相HPLC硅胶吸附物作为内标进行蒜辣素的含量测定。另外我们还建立了两种洗脱系统以缩短分析时间而获得相同的分析数据。蒜辣素的保留时间原为6.7min,而现在的保留时间分别减少到3.5和3.9min。为了建立蒜氨酸的内标,我们改进了氨基酸的合成方法,异构体反复重结晶进行分离,用HPLC进行蒜氨酸定量测定。 相似文献
6.
目的测定和分析大蒜抗氧化活性成分。方法利用1,1-二苯基苦基苯肼法(DPPH·)测定大蒜灭酶体系和蒜酶激活体系抗氧化活性成分,利用大蒜氨基酸展开系统(正丁醇-冰乙酸-水)、大蒜辣素展开系统(甲苯-乙酸乙酯)和大蒜多糖展开系统(冰乙酸-氯仿-水)对大蒜抗氧化活性成分进行分析。结果大蒜灭酶体系中氨基酸、大蒜多糖和蒜酶激活体系中的大蒜含硫化合物的半数抑制质量浓度(IC50)分别为0.058,0.170和0.068mg·mL-1。大蒜灭酶体系中的蒜氨酸和蒜酶激活体系中的大蒜辣素有抗氧化活性,其他抗氧化活性成分有待进一步确定。结论大蒜中氨基酸和含硫化合物有一定的抗氧化活性,具有研究价值。 相似文献
7.
一种新制剂内含有活性的蒜酶和蒜氨酸的干大蒜提取物。据蒜酶量计,干大蒜提取残渣中比大蒜粉含有更多的蒜氨酸,也含至少0.1%的粉状水溶性酸,至少2%的蒜氨酸(千重)。不含蒜酶,仅含蒜氨酸的大蒜提取物 相似文献
8.
9.
目的:建立准确、方便的 HPLC 法测定鲜蒜中蒜氨酸。方法:采用微波灭酶,以利巴韦林为内标物,HPLC 紫外检测,测定鲜蒜中蒜氨酸含量。与美国药典蒜氨酸衍生化 HPLC 测定进行比较。结果:同一鲜蒜样品测定蒜氨酸含量,以微波法灭酶大蒜的含量最高,为1.291%(RSD=1.4%),回收率为98.80(±2.0)%;美国药典方法测定结果为1.287%(RSD=3.6%),回收率为96.03(±2.6)%。结论:HPLC 内标法与美国药典方法测定结果一致,操作步骤简化。 相似文献
10.
11.
目的:制备胸腺肽α1结肠释放片(Tα1片),评价其体外释药性能。方法:将Tα1制成片芯,2次包衣,内层为壳聚糖盐酸盐,外层为尤特奇L100-55。高效液相色谱(HPLC)法进行含量及含量均匀度测定,扫描电镜法评价壳聚糖盐酸盐包衣膜在模拟大肠液中的降解作用。以荧光剂FD-4为模型化合物,同法制备模拟结肠片,荧光分光光度法检测其在pH 1.2盐酸溶液,pH 6.8磷酸盐缓冲液及模拟大肠液中的体外释放性能。结果:Tα1片的含量及含量均匀度符合《中国药典》相关规定;电镜扫描结果表明,壳聚糖盐酸盐包衣膜在模拟大肠液中具有显著降解作用;模拟结肠片在pH 1.2盐酸溶液和pH 6.8磷酸盐缓冲液中的累积释药量6 h内小于23%,而在模拟大肠液中4 h基本释药完全。结论:本研究所制备的Tα1结肠释放片具有潜在的结肠靶向释药效果。 相似文献
12.
目的:制备陈香露白露薄膜衣片,提高药物稳定性。方法:选用不同的粘合剂制备片芯,再选用不同的包衣材料进行包衣,比较陈香露白露薄膜衣片与糖衣片的稳定性。结果:采用10%聚乙烯吡咯烷酮乙醇液为粘合剂制备片芯,用隔离材料玉米阮将片芯保护,采用上海卡乐康公司的黄色或红棕色胃溶性包衣粉制备的陈香露白露薄膜衣片在外观质量上优于其它材料制备的成品,尤其是防渗油和防潮性方面优势明显;薄膜衣片稳定性优于糖衣片。结论:陈香露白露薄膜衣片质量稳定,制备工艺简单。 相似文献
13.
In the present study, gastric juice resistant tablet formulations of lactic acid bacteria (LAB) were developed, using hydroxypropylmethylcellulose acetate succinate (HPMCAS) as well as alginates, apple pectin and Metolose as matrix forming components. To optimize the formulation-using survival rate in acid medium, and disintegration time in intestinal fluid as test parameters-tablets were modified with respect to LAB content, amount of applied excipients per tablet, and compaction forces. A decrease of viable cells of not more than one log unit after 2h of incubation in acid medium was desired, as well as a disintegration time of 1h in phosphate buffer pH 6.8. It was found that the amount of HPMCAS in the tablet correlates with gastric juice resistance. As HPMCAS also leads to a decrease of disintegration time in intestinal fluid, slight amounts of this excipient were preferred. The best protective qualities against artificial gastric juice were observed when tablets were prepared from compaction mixtures of LAB, HPMCAS and sodium alginate. 相似文献
14.
盐酸吗啡普通片及硫酸吗啡控释片在不同溶剂中溶释过程的对照研究 总被引:2,自引:0,他引:2
本文采用紫外分光光度法对国产盐酸吗啡普通片及合资厂产硫酸吗啡控释片于蒸馏水、人工胃液、人工肠液中进行体外溶出度和释放度测定。结果表明,两种片剂的溶释均符合中国药典95版标准,控释片在人工肠液中溶释参数T50、Td、m与在蒸馏水及人工胃液中的溶释参数差异具显著性(P<0.01),在人工肠液中的释放过程明显缓慢。 相似文献
15.
The aim of this study was to prepare the rosiglitazone sodium enteric-coated tablets and investigate its release rate. The rosiglitazone sodium enteric-coated tablet was prepared by single punch tablet press using substituted hydroxypropyl cellulose and polyvinylpyrrolidone (PVP). The release rate from the enteric-coated tablet of rosiglitazone sodium was evaluated. The release rate study showed that few rosiglitazone sodium was released from enteric coated formulation within 2 h in simulated gastric juice, while it released more than 80% of the labeled amount in 30 min in simulated intestinal juice. The preparing method of rosiglitazone sodium enteric-coated tablets was simple and had a good reproducibility. The release condition and determined methods could be used for the routine determinations of rosiglitazone sodium enteric-coated tablets. 相似文献
16.
17.
盐酸黄连素微囊溶出度的研究 总被引:15,自引:1,他引:14
本文报道采用微囊技术掩盖黄连素的苦味,通过对溶出度的研究表明,该品在人工胃液、肠液中的溶出度与片剂无显著差异,对治疗作用亦无影响,解决了儿童服药不便的难题。 相似文献
18.
19.
目的:建立川葛分散片中葛根素溶出度的测定方法。方法:依据《中国药典》2010版附录中转篮法测定溶出度,于不同时间取样,用紫外可见分光光度法在波长为250nm处测定葛根素的含量,计算川葛分散片的累积释放度。结果:该法加样回收率为97.57%,RSD为1.24%,在1.05-10.50μg·mL-1范围内浓度和峰面积呈良好的线性关系。使用该试验确定的方法,10min时测定川葛分散片的累积溶出百分率达到标示量的100.92%。结论:该方法简便易行、准确可靠,可用于川葛分散片的质量控制。 相似文献
20.
Development and in vitro evaluation of expandable gastroretentive dosage forms based on compressed collagen sponges 总被引:1,自引:0,他引:1
The objective of this study was to develop and evaluate new collagen gastroretentive dosage forms (GRDFs) which expand in the stomach after contact with gastric fluids. The GRDFs should remain in the stomach for a prolonged period of time due to their size. The dosage forms were prepared from collagen sponges. The sponges were manufactured by freeze-drying a riboflavin-containing collagen solution. A computer controlled material supply was constructed to transport precompressed collagen into a tablet machine. A second type of tablet was manufactured by combining compressed collagen sponges with hydrophilic matrix layers of hydroxypropylmethylcellulose. Matrix layers containing captopril or aciclovir were developed. In vitro experiments were performed with both types of dosage forms. The collagen tablets expand within a few minutes after contact with artificial gastric juice and form a drug delivery system with a size of 8 mm x 18 mm x 60 mm. Riboflavin is released over 16 h. If two layer tablets are used, the release of aciclovir or captopril can be controlled by the composition of the sustained release layer. 相似文献